Skip to main content

MoneyWorks4Me

Kopran - Quaterly Results

04 Nov 2026 Evaluate
The Total revenue for the quarter ended September 2026 of  Rs. 871.18 millions grew by 105.52% from Rs. 423.89 millions.The Total Profit for the quarter ended September 2026 of Rs. 62.85 millions grew from Rs.-39.93 millions Operating profit Margin for the quarter ended September 2026 improved to 111.81% as compared to -28.83% of corresponding quarter ended September 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 871.18 423.89 105.52 1498.76 937.24 59.91 3056.46 2710.10 12.78
Other Income 8.61 3.23 166.56 37.75 21.21 77.98 19.99 59.04 -66.14
PBIDT 111.81 -28.83 -487.83 225.49 39.85 465.85 495.75 445.60 11.25
Interest 13.86 8.25 68.00 26.24 18.67 40.55 42.00 37.66 11.52
PBDT 97.95 -37.08 -364.16 199.25 21.18 840.75 453.75 407.94 11.23
Depreciation 13.86 11.62 19.28 27.34 23.81 14.83 49.81 49.99 -0.36
PBT 84.09 -48.70 -272.67 171.91 -2.63 -6636.50 403.94 357.95 12.85
TAX 21.24 -8.77 -342.19 41.85 2.12 1874.06 99.94 89.38 11.81
Deferred Tax 1.78 2.03 -12.32 3.06 2.12 44.34 9.58 3.06 213.07
PAT 62.85 -39.93 -257.40 130.06 -4.75 -2838.11 304.00 268.57 13.19
Equity 483.26 482.86 0.08 483.26 482.86 0.08 482.86 482.86 0.00
PBIDTM(%) 12.83 -6.80 -288.70 15.05 4.25 253.85 16.22 16.44 -1.35
Peers
Company Name CMP
Sun Pharma. Inds. 1903.00
Dr. Reddys Labs. 1398.00
Cipla 1416.00
Lupin 1999.00
Zydus Lifesciences 1200.00
View more..